Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (281)	11/19/2003 8:11:48 PM
From: SemiBull	Read Replies (1) \| Respond to of 286

Focusing on biotech: SunAmerica manager likes Genzyme, Pozen, Nuvelo "...One biotech firm Clifford especially likes is Nuvelo (NUVO: news, chart, profile), which has an experimental clot-busting drug now being tested on patients. Sunnyvale, Calif.-based Nuvelo is small and the risk of a clinical setback with its experimental drug remains. But Clifford said he's optimistic about the company's prospects partly because of a partnership with Amgen (AMGN: news, chart, profile), the world's largest biotechnology firm. Nuvelo shares gained 18 cents to $3.64 on Tuesday...." marketwatch.com